<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542135</url>
  </required_header>
  <id_info>
    <org_study_id>STOP-BC Trial</org_study_id>
    <nct_id>NCT04542135</nct_id>
  </id_info>
  <brief_title>Sulindac and Breast Density in Women at Risk of Developing Breast Cancer</brief_title>
  <official_title>Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a&#xD;
      day for 12 months reduces breast density in postmenopausal women at elevated risk of breast&#xD;
      cancer when compared to a placebo control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent breast density by MRI</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in collagen type in breast tissue by whole slide mass spectrometry of tissue biopsy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in collagen fiber alignment by second harmonic generation microscopy in breast tissue by biopsy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Sulindac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sulindac 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulindac Pill</intervention_name>
    <description>Randomized participants will receive either 150 mg oral sulindac twice daily.</description>
    <arm_group_label>Sulindac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pills twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¤70 years&#xD;
&#xD;
          2. Subject must be postmenopausal.&#xD;
&#xD;
          3. Must have at least one healthy normal appearing breast (no prior diagnosis of invasive&#xD;
             cancer, radiation or prosthetics). Prior biopsies are acceptable.&#xD;
&#xD;
          4. Must have dense breasts&#xD;
&#xD;
          5. Must be at elevated risk for developing breast cancer by abnormal pathological&#xD;
             findings, family history, or genetic predisposition&#xD;
&#xD;
          6. A negative fecal occult blood test&#xD;
&#xD;
          7. Normal organ function&#xD;
&#xD;
          8. Hormonal therapy with aromatase inhibitors is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Daily aspirin or other daily anti inflammatory use.&#xD;
&#xD;
          2. Known intolerance to anti inflammatory.&#xD;
&#xD;
          3. Use of any selective estrogen receptor modulator therapy (e.g., tamoxifen, raloxifene)&#xD;
             within past 12 months&#xD;
&#xD;
          4. Gastrointestinal, bleeding or coagulation, cardiovascular disorders.&#xD;
&#xD;
          5. Diabetes requiring insulin therapy.&#xD;
&#xD;
          6. Current regular smoker.&#xD;
&#xD;
          7. History of claustrophobia or inability to undergo imaging in a closed magnetic&#xD;
             resonance imaging.&#xD;
&#xD;
          8. Cardiac pacemaker, cochlear implants, magnetic surgical clips or prostheses that would&#xD;
             preclude MRI.&#xD;
&#xD;
          9. Uncontrolled hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison S Stopeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia A Thompson-Carino, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pushpa Talanki</last_name>
    <phone>631-638-0815</phone>
    <email>pushpa.talanki@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Molly Rago, RN</last_name>
    <phone>631-638-0852</phone>
    <email>molly.rago@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pushpa Talanki</last_name>
      <phone>631-638-0815</phone>
      <email>pushpa.talanki@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Molly Rago, RN</last_name>
      <phone>631-638-0852</phone>
      <email>molly.rago@stonybrookmedicine.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alison Stopeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Patricia Thompson-Carino</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data to non study related researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

